1	Title: Anxiety disorders and age-related changes in physiology
2	
3	Short title: Physiological changes in anxiety disorders
4	
5	Authors: Julian Mutz <sup>1*</sup> , Thole H. Hoppen <sup>2</sup> , Chiara Fabbri <sup>1,3</sup> and Cathryn M. Lewis <sup>1,4</sup>
6	
7	Affiliations:
8	1. Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology &
9	Neuroscience, King's College London, London, United Kingdom.
10	2. Institute of Psychology, University of Münster, Münster, Germany.
11	3. Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
12	4. Department of Medical and Molecular Genetics, Faculty of Life Sciences & Medicine, King's
13	College London, London, United Kingdom.
14	
15	*Corresponding author:
16	Julian Mutz; Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry,
17	Psychology & Neuroscience, King's College London, Memory Lane, London SE5 8AF, United

18 Kingdom. Email: julian.mutz@gmail.com.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 19 Abstract

- Background: Anxiety disorders are leading contributors to the global disease burden, highly prevalent
   across the lifespan, and associated with substantially increased morbidity and early mortality.
- 22 Aims: The aim of this study was to examine age-related changes across a wide range of physiological
- measures in middle-aged and older adults with a lifetime history of anxiety disorders compared tohealthy controls.
- 25 Method: The UK Biobank study recruited >500,000 adults, aged 37–73, between 2006–2010. We used
- 26 generalised additive models to estimate non-linear associations between age and hand-grip strength,
- 27 cardiovascular function, body composition, lung function and heel bone mineral density in cases and in
- 28 controls.
- 29 **Results:** The main dataset included 332,078 adults (mean age = 56.37 years; 52.65% females). In both
- 30 sexes, individuals with anxiety disorders had a lower hand-grip strength and blood pressure, while their
- 31 pulse rate and body composition measures were higher than in healthy controls. Case-control
- 32 differences were larger when considering individuals with chronic and/or severe anxiety disorders, and
- 33 differences in body composition were modulated by depression comorbidity status. Differences in age-
- 34 related physiological changes between female anxiety disorder cases and healthy controls were most
- 35 evident for blood pressure, pulse rate and body composition, while in males for hand-grip strength,
- 36 blood pressure and body composition. Most differences in physiological measures between cases and
- 37 controls decreased with increasing age.
- 38 Conclusions: Individuals with a lifetime history of anxiety disorders differed from healthy controls
   39 across multiple physiological measures, with some evidence of case-control differences by age. The
- 40 differences observed varied by chronicity/severity and depression comorbidity.
- 41
- 42 Keywords: Ageing; Anxiety; Body composition; Cardiovascular function; Physiology

# 43 Introduction

44

45 Anxiety disorders are leading contributors to the global disease burden, highly prevalent across the 46 lifespan and across nations, and associated with substantially increased morbidity and early mortality(1-47 4). A population-based study from Denmark reported that individuals with anxiety disorders had a 39% 48 higher risk of premature death than the general population(5). This excess mortality does not result only 49 from unnatural causes of death such as suicide, but also from increased rates of dementia, cardiovascular 50 disease and other illnesses. Anxiety disorders are also associated with accelerated biological ageing, 51 including earlier neurodegeneration(6, 7) and telomere attrition(8, 9), and an increased risk of disability 52 in old age, especially in individuals with comorbid depression(10, 11). Less is known about 53 physiological differences between individuals with anxiety disorders and healthy controls, and whether 54 such differences vary by age. A Dutch longitudinal study reported that individuals with anxiety 55 disorders had poorer lung function than healthy controls, and that men with anxiety disorders showed 56 a greater decline in lung function over time(12). Women with anxiety disorders also had a lower hand-57 grip strength. More severe anxiety disorders were associated with greater physiological abnormalities. 58 Most studies of physiology in anxiety disorders have focussed on one or two physiological 59 measures (12-14) and research examining a range of physiological measures is lacking. To the best of 60 our knowledge, this is the first study to examine age-related changes across a wide range of 61 physiological measures in middle-aged and older adults with anxiety disorders. Most physiological 62 measures can be assessed non-invasively, fast and at low cost, while providing reliable information on 63 functional decline. Importantly, variation in physiological functioning predicts morbidity and mortality. 64 A greater understanding of age-related physiological changes in anxiety disorders may inform strategies 65 for prevention and intervention to foster healthy ageing.

66

#### 67 Aims

68 The aim of this cross-sectional study was to examine associations between age and 15 physiological 69 markers in individuals with a lifetime history of anxiety disorders compared to healthy controls. Since 70 the epidemiology of anxiety disorders(2) and human physiology(15) differ by sex, we conducted 71 separate analyses in males and females. Given that a dose-response relationship between anxiety 72 disorder severity and differences in physiology has been reported before(12), we also examined chronic 73 and/or severe anxiety disorders. Finally, depression has been associated with age-related changes in 74 physiology(16) and is highly comorbid with anxiety disorders(2-4, 12), hence we also examined 75 individuals with anxiety disorders without comorbid depression.

76

# 77 Method

## 78

### 79 Study population

80 The UK Biobank is a prospective study of >500,000 adults aged 37–73 at baseline, recruited between 81 2006–2010. The study rationale and design have been described elsewhere(17). Briefly, individuals 82 registered with the UK National Health Service (NHS) and living within a ~40 km radius of one of 22 assessment centres were invited to participate. Participants provided information on their 83 84 sociodemographic characteristics, lifestyle and medical history and underwent physical examination. 85 Hospital inpatient records are available for most participants and primary care records are currently 86 available for half of participants. A subset of 157,366 out of 339,092 invited participants (46%) 87 completed an online follow-up mental health questionnaire (MHQ) between 2016 and 2017, covering 88 31% of all participants.

89

## 90 Exposures

91 Age at the baseline assessment was the primary explanatory variable.

92

93 Details of the definition of cases and healthy controls are presented in Supplement 1. Briefly, we used 94 a transdiagnostic phenotype for lifetime anxiety disorders and identified cases from multiple sources: 95 the generalised anxiety disorder module of the Composite International Diagnostic Interview Short 96 Form (CIDI-SF) (Supplement 2)(18) and the Generalised Anxiety Disorder Assessment (GAD-7)(19), 97 which were assessed through the MHQ; psychiatric diagnoses reported during the nurse-led interview 98 at baseline or in the MHQ; hospital inpatient records (Supplement 3); primary care records(20) 99 (Supplement 4). We excluded individuals with bipolar disorder or psychosis, as these disorders are 100 strongly associated with the risk of physical multimorbidity(21, 22). Healthy controls had no anxiety 101 disorders, reported no current psychotropic medication use at baseline (Supplement 5)(23) and had no 102 other mental disorders: no psychiatric diagnosis according to the nurse-led interview, MHQ, hospital 103 inpatient or primary care records; no probable mood disorder(24) (Supplement 6); no Patient Health 104 Ouestionnaire-9 (PHO-9) sum score of >5; no GAD-7 sum score of >5; did not report ever feeling 105 worried, tense, or anxious for most of a month or longer; no depression or bipolar disorder based on the 106 CIDI-SF depression module and questions on (hypo)manic symptoms(16, 25).

107

#### 108 Physiological measures

109 We examined 15 physiological measures obtained at the baseline assessment, including maximal hand-

110 grip strength, systolic and diastolic blood pressure, pulse rate, body mass index (BMI), waist-hip ratio,

- 111 fat mass, fat-free mass, body fat percentage, peak expiratory flow, forced vital capacity (FVC), forced
- 112 expiratory volume in one second (FEV<sub>1</sub>),  $FVC/FEV_1$  ratio, heel bone mineral density and arterial

stiffness. Details of these measures have previously been reported in our study on age-related physiological changes in depression(16) and are presented in Supplement 7.

115

### 116 Exclusion criteria

- 117 Participants whose genetic and self-reported sex did not match and participants with missing data,
- 118 including "do not know" or "prefer not to answer", for any covariates were excluded.
- 119

### 120 Covariates

121 and Covariates were identified from previous studies included ethnicity, highest 122 educational/professional qualification(26), physical activity (walking, moderate and vigorous-intensity 123 activity), smoking status, alcohol intake frequency, sleep duration and, for cardiovascular measures, 124 antihypertensive medication use (fields 6153 and 6177). Details of the sociodemographic and lifestyle

- 125 factors are available in our previous publication(27).
- 126

## 127 Statistical analyses

- 128 Analyses were prespecified prior to inspection of the data (preregistration: osf.io/hqu2f) and algorithms
- 129 were tested on simulated data. Statistical analyses were conducted using R (version 3.6.0).
- 130

Sample characteristics were summarised using means and standard deviations or counts and
 percentages. Case-control differences were estimated using standardised mean differences (± 95%
 confidence intervals).

134

135 We examined the relationship between each physiological measure and age using generalised additive 136 models (GAMs) with the 'mgcv' package in R(28). GAMs are flexible modelling approaches that allow 137 for the relationship between an outcome variable and a continuous exposure to be represented by a non-138 linear smooth curve while adjusting for covariates. This approach is useful if a linear model does not 139 capture key aspects of the relationship between variables and attempts to achieve maximum goodness-140 of-fit while maintaining parsimony of the fitted curve to minimize overfitting. Smoothing parameters 141 were selected using the restricted maximum likelihood method and we used the default option of ten 142 basis functions to represent smooth terms. Each measure was modelled against a penalised regression 143 spline function of age with separate smooths for anxiety disorder cases and healthy controls. 144 145 Two models were fitted for each physiological measure in males and females separately:

- 146
- Unadjusted model: physiological measure  $\sim$  anxiety disorder + s(age, by anxiety disorder).
- Adjusted model: physiological measure ~ anxiety disorder + s(age, by anxiety disorder) +
   covariates (see previous paragraph).

150

151 where *s(age, by anxiety disorder)* represents the smooth function for age, stratified by anxiety disorder 152 status.

153

To formally test whether the relationships between physiological measures and age differed between anxiety disorder cases and controls, we also fitted models that included reference smooths for healthy controls and difference smooths for anxiety disorder cases compared to healthy controls. For these analyses, anxiety disorder status was coded as an ordered factor in R. If the difference smooth differs from zero, the physiological measure follows a different trend with age in anxiety disorder cases and healthy controls.

160

161 Adjusted *p*-values were calculated using the *p.adjust* function in R to account for multiple testing across 162 each set of analyses of the 15 physiological measures. Two methods were used: (1) Bonferroni and (2) 163 Benjamini & Hochberg(29), two-tailed with  $\alpha = .05$  and false discovery rate of 5%, respectively. We 164 have opted for this approach because the standard Bonferroni correction is usually too conservative,

165 potentially leading to a high number of false negatives.

166

In a secondary analysis, we examined individuals with chronic and/or severe anxiety disorders, defined as individuals with (i) a hospital inpatient record of anxiety disorders as the primary diagnosis, (ii) recurrent or chronic anxiety (E2004 or E2005) in their primary care record or (iii) generalised anxiety disorder according to the CIDI-SF with maximum level of impairment ("Impact on normal roles during worst period of anxiety" (field 20418) = A lot) and duration ("Longest period spent worried or anxious" (field 20420) = All my life / as long as I can remember or at least 24 months).

173

174 In a sensitivity analysis, we excluded individuals with depression comorbidity from anxiety disorder175 cases(16).

176

177 We conducted two additional sensitivity analyses that were not pre-registered: (i) we additionally

178 adjusted analyses of cardiovascular measures for BMI and (ii) we excluded anxiety disorder cases who

179 reported current use of antidepressants at baseline from the analyses of blood pressure.

# 180 **Results**

### 181

#### 182 Study population

- 183 A subset of 444,690 (88.49%) participants had complete data on all covariates. After excluding
- 184 participants with missing physiological data, unclear anxiety disorder status (n = 93) or not meeting
- 185 our inclusion criteria, we retained 332,078 participants in the main dataset. Subsets of 123,597, 228,321
- and 107,958 participants were included in the analyses of lung function, heel bone mineral density and
- 187 arterial stiffness, respectively (Supplement Figure 1).

#### 188 Sample characteristics

- 189 The average participant age in our main dataset was 56.37 years (SD = 8.11) and 52.65% of
- 190 participants were female. Overall, 44,722 (13.47%) participants in this sample had a lifetime history of
- 191 anxiety disorders, 65.92% (n = 29,482) of whom were female. Descriptive statistics for the full UK
- 192 Biobank and for the analytical samples stratified by sex and anxiety disorder status are presented in
- 193 Table 1 (physiological measures) and Supplement Table 4 (covariates).

			Fen	nale	Male		
	Overall ( <i>N</i> =502,521)		Healthy control ( <i>N</i> =145,364)	Anxiety disorder (N=29,482)	Healthy control (N=141,992)	Anxiety disorder ( <i>N</i> =15,240)	
	Mean (SD)	Missing	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	
Hand-grip strength	31.77 (11.34)	3203	24.89 (6.48)	24.68 (6.64)	41.25 (9.11)	40.53 (9.22)	
Systolic blood pressure	137.87 (18.65)	1325	135.71 (19.32)	133.23 (18.48)	141.28 (17.42)	139.63 (16.92)	
Diastolic blood pressure	82.26 (10.15)	1323	80.70 (9.96)	80.29 (9.91)	84.22 (9.96)	83.92 (9.93)	
Pulse rate	69.42 (11.26)	1323	69.87 (10.40)	70.33 (10.68)	67.76 (11.60)	68.66 (12.04)	
Body mass index	27.43 (4.80)	3105	26.66 (4.85)	26.89 (5.20)	27.64 (4.02)	27.76 (4.33)	
Body fat percentage	31.45 (8.55)	10408	36.06 (6.74)	36.40 (6.96)	24.97 (5.63)	25.27 (5.81)	
Fat mass	24.86 (9.57)	10973	26.14 (9.50)	26.83 (10.23)	21.87 (7.88)	22.37 (8.48)	
Fat-free mass	53.22 (11.50)	10176	44.33 (4.84)	44.62 (5.05)	63.67 (7.62)	63.80 (7.89)	
Waist-hip ratio	0.87 (0.09)	2265	0.81 (0.07)	0.82 (0.07)	0.93 (0.06)	0.94 (0.06)	
			N=50,729	N=10,128	<i>N</i> =56,695	<i>N</i> =6,045	
Peak expiratory flow	407.82 (130.78)	168566	352.52 (76.81)	356.88 (77.84)	510.07 (115.61)	509.72 (115.63)	
Forced expiratory volume 1s	2.85 (0.78)	149197	2.48 (0.53)	2.51 (0.53)	3.43 (0.74)	3.44 (0.74)	
Forced vital capacity	3.78 (0.98)	149197	3.25 (0.64)	3.30 (0.65)	4.57 (0.88)	4.58 (0.89)	
FEV <sub>1</sub> / FVC	0.75 (0.07)	149197	0.76 (0.06)	0.76 (0.06)	0.75 (0.07)	0.75 (0.07)	
			N=101,279	<i>N</i> =19,217	<i>N</i> =97,749	<i>N</i> =10,076	
Heel bone mineral density	0.54 (0.14)	180831	0.52 (0.12)	0.52 (0.12)	0.58 (0.15)	0.57 (0.15)	
			<i>N</i> =45,320	N=10,630	<i>N</i> =46,549	N=5,459	
Arterial stiffness	9.34 (4.05)	332721	8.72 (4.27)	8.71 (3.33)	9.94 (4.59)	9.94 (2.92)	

#### Table 1. Physiological measures

*Note:* SD = standard deviation;  $FEV_1 = forced expiratory volume in one second; FVC = forced vital capacity.$ 

### 194 Case-control differences

195 Case-control differences by sex are presented in Table 2. Females with anxiety disorders had a lower

- 196 hand-grip strength and blood pressure than healthy controls. Their pulse rate was elevated, and they had
- 197 higher values for all body composition measures and most lung function measures than controls. We
- 198 did not find evidence of differences in the FEV<sub>1</sub>/FVC ratio, heel bone mineral density or arterial

perpetuity. It is made available under a CC-BY 4.0 International license .

- 199 stiffness. Male anxiety disorder cases had a lower hand-grip strength, blood pressure and heel bone 200 mineral density than healthy controls. Their pulse rate and all body composition measures were higher
- 201 than in controls, although the difference in fat-free mass did not survive multiple testing correction. We
- 202 did not find evidence of differences in lung function or arterial stiffness in males. The largest case-
- 203 control difference was observed for systolic blood pressure (SMD = -0.129,95% CI -0.142 to -0.117,
- 204  $p_{\text{Bonf.}} < 0.001$  in females and SMD = -0.091, 95% CI -0.111 to -0.078,  $p_{\text{Bonf.}} = 0.013$  in males).

Table 2. Differences in physiological measures between individuals with anxiety disorders and healthy controls										
	Male									
Variable	SMD	95% CI		$p_{\mathrm{Bonf.}}$	$p_{\rm BH}$	SMD	95% CI		$p_{ m Bonf.}$	$p_{ m BH}$
Hand-grip strength	-0.032	-0.044	-0.019	< 0.001	< 0.001	-0.079	-0.096	-0.062	< 0.001	< 0.001
Systolic blood pressure	-0.129	-0.142	-0.117	< 0.001	< 0.001	-0.095	-0.111	-0.078	< 0.001	< 0.001
Diastolic blood pressure	-0.041	-0.053	-0.028	< 0.001	< 0.001	-0.030	-0.046	-0.013	0.007	0.001
Pulse rate	0.045	0.032	0.057	< 0.001	< 0.001	0.078	0.061	0.095	< 0.001	< 0.001
Body mass index	0.047	0.035	0.060	< 0.001	< 0.001	0.029	0.013	0.046	0.017	0.002
Body fat percentage	0.050	0.038	0.063	< 0.001	< 0.001	0.054	0.037	0.070	< 0.001	< 0.001
Fat mass	0.071	0.059	0.084	< 0.001	< 0.001	0.063	0.046	0.080	< 0.001	< 0.001
Fat-free mass	0.058	0.046	0.071	< 0.001	< 0.001	0.017	0.000	0.034	0.831	0.083
Waist-hip ratio	0.044	0.031	0.056	< 0.001	< 0.001	0.091	0.074	0.107	< 0.001	< 0.001
Peak expiratory flow	0.057	0.035	0.078	< 0.001	< 0.001	-0.003	-0.029	0.024	>0.999	0.886
Forced expiratory volume 1s	0.064	0.042	0.085	< 0.001	< 0.001	0.010	-0.017	0.036	>0.999	0.582
Forced vital capacity	0.067	0.045	0.088	< 0.001	< 0.001	0.013	-0.013	0.040	>0.999	0.442
FEV1 / FVC	0.011	-0.010	0.033	>0.999	0.347	-0.005	-0.031	0.022	>0.999	0.844
Heel bone mineral density	-0.005	-0.021	0.010	>0.999	0.538	-0.067	-0.088	-0.047	< 0.001	< 0.001
Arterial stiffness	-0.003	-0.025	0.018	>0.999	0.712	-0.001	-0.029	0.027	>0.999	0.927

*Note:* SMD = standardised mean difference; CI = confidence interval; Bonf. = Bonferroni; BH = Benjamini & Hochberg;  $FEV_1$  = forced expiratory volume in one second; FVC = forced vital capacity. *P*-values for Welch's t-test. Negative values correspond to lower values in anxiety disorder cases.

### 205 Chronic and/or severe anxiety

206 Between 8.37% to 9.46% of female and 9.47% to 9.99% of male cases had chronic and/or severe anxiety 207 disorders (Supplement Table 5). In females, we observed the same overall pattern of results as in the main analysis, although all observed differences were larger in magnitude. For example, the case-208 209 control difference in body fat percentage was SMD = 0.113 (95% CI 0.074-0.151,  $p_{Bonf.} < 0.001$ ) (Supplement Table 6), compared to SMD =  $0.050 (95\% \text{ CI } 0.038 - 0.063, p_{Bonf.} < 0.001)$  in the main 210 211 analysis. In male chronic and/or severe cases, we did not find evidence of a difference in diastolic blood 212 pressure compared to healthy controls (SMD = -0.013, 95% CI -0.064 to  $0.038, p_{BH} = 0.713$ ) and the 213 difference in body fat percentage was not statistically significant after multiple testing correction. For 214 most other physiological measures, we observed larger case-control differences than in the main 215 analysis (Supplement Table 6). For example, the case-control difference in systolic blood pressure was 216 SMD = -0.095 (95% CI -0.111 to -0.078,  $p_{Bonf.} < 0.001$ ) in the main analysis and SMD = -0.153 217 (95% CI -0.204 to -0.102,  $p_{Bonf.} < 0.001$ ) in this analysis. 218

219 Anxiety without depression comorbidity

220 After excluding anxiety disorder cases with depression comorbidity, we retained between 25.91% to

221 37.67% of female and 31.45% to 44.69% of male cases (Supplementary Table 5). In females,

differences in hand-grip strength, blood pressure, pulse rate and arterial stiffness remained statistically 222 223 significant but were smaller in magnitude than in the main analysis (Supplement Table 7). Body mass 224 index, fat mass and fat-free mass, which were higher in cases than in controls in the main analysis, were 225 lower in cases without depression comorbidity (SMDs between -0.026 and -0.049). We did not find 226 evidence of case-control differences in body fat percentage or waist-hip ratio in this analysis. There was 227 also no longer evidence of differences in lung function, except that the FEV<sub>1</sub>/FVC ratio was lower in 228 cases than in controls (SMD = -0.048, 95% CI -0.082 to -0.013,  $p_{BH} = 0.019$ ). Finally, heel bone 229 mineral density was lower in female cases (SMD = -0.036, 95% CI -0.060 to  $-0.012, p_{Bonf.} = 0.043$ ). 230 In males, differences in hand-grip strength, blood pressure, pulse rate, waist-hip ratio, lung function, 231 heel bone mineral density and arterial stiffness were similar to the main analysis. Body mass index and 232 fat-free mass were lower in cases than in controls (SMD = -0.058, 95% CI -0.084 to  $-0.033, p_{Bonf} <$ 233 0.001 and SMD = -0.066, 95% CI -0.092 to  $-0.041, p_{Bonf.} < 0.001$ , respectively) and we did not find 234 evidence of case-control differences in body fat percentage or fat mass, which were elevated in cases 235 in the main analysis. 236

#### 237 **Case-control differences by age**

238 We found some evidence that age-related changes in blood pressure, pulse rate, body composition and 239 heel bone mineral density differed between female cases and controls (Figure 1). Systolic blood 240 pressure was -0.9 mmHg lower in cases at age 45 and this difference widened to -2.2 mmHg at age 65. 241 For diastolic blood pressure, we did not find evidence of case-control differences below age 52, and 242 slightly lower diastolic blood pressure in cases than in controls above age 52. Case-control differences 243 in pulse rate and body composition narrowed with age (Supplement Figure 2). Heel bone mineral 244 density was slightly lower in cases than in controls below age 55, and there was no evidence of 245 differences between older cases and controls.

perpetuity. It is made available under a CC-BY 4.0 International license .



Figure 1. Generalised additive models of age-related changes in physiological measures in females with anxiety disorders and healthy controls. The solid lines represent physiological measures against smoothing functions of age. The shaded areas correspond to approximate 95% confidence intervals ( $\pm 2 \times$  standard error). FEV<sub>1</sub> = forced expiratory volume in one second; FVC = forced vital capacity.

246 In males, case-control differences in hand-grip strength, pulse rate, waist-hip ratio and heel bone 247 mineral density narrowed with age (Figure 2 and Supplement Figure 3). There was some evidence 248 that diastolic blood pressure was lower in cases than in controls above age 50, although the formal 249 statistical test did not survive multiple testing correction. We found little evidence of case-control 250 differences by age for the other physiological measures.



Figure 2. Generalised additive models of age-related changes in physiological measures in males with anxiety disorders and healthy controls. The solid lines represent physiological measures against smoothing functions of age. The shaded areas correspond to approximate 95% confidence intervals ( $\pm 2 \times$  standard error). FEV<sub>1</sub> = forced expiratory volume in one second; FVC = forced vital capacity.

251 In females, we observed similar results across all physiological measures after adjustment for covariates 252 (Supplement Figures 4 and 5). The formal statistical tests provided no evidence of case-control 253 differences in age-related changes in heel bone mineral density, however, the overall pattern of results 254 was comparable to the unadjusted model. In males, we also observed similar results in the adjusted 255 model (Supplement Figures 6 and 7). Although the trajectories were similar to the unadjusted analysis, 256 the formal statistical tests provided no evidence of case-control differences in age-related changes in

waist-hip ratio. The same was true for diastolic blood pressure and heel bone mineral density aftermultiple testing correction.

259

#### 260 *Chronic and/or severe anxiety*

261 In female chronic and/or severe cases, we observed similar results for age-related changes in blood 262 pressure and body composition, except that there was no evidence of case-control differences in fat-263 free mass below age 45 (Supplement Figures 8 and 9). As in the main analysis, we observed no 264 evidence of case-control differences in age-related changes in lung function or arterial stiffness. 265 Differences in results were most evident for hand-grip strength and pulse rate, and to a lesser extent for 266 heel bone mineral density. The formal statistical tests provided some evidence of case-control 267 differences in age-related changes in blood pressure, body mass index, fat mass and fat-free mass, 268 although none survived multiple testing correction. For male chronic and/or severe cases, we found 269 some evidence that case-control differences in hand-grip strength and pulse rate narrowed with age, 270 similar to the results from the main analysis, although none of the formal statistical tests survived 271 multiple testing correction. There was less evidence of case-control differences in age-related changes 272 in systolic blood pressure and no evidence of case-control differences in age-related changes in diastolic 273 blood pressure. For all other physiology measures, none of the formal statistical tests were statistically 274 significant (Supplement Figures 10 and 11).

275

### 276 Anxiety without depression comorbidity

277 In female cases without depression comorbidity, none of the formal statistical tests provided evidence 278 of case-control differences in age-related changes in physiology. We also observed less evidence of 279 differences by age in blood pressure or pulse rate. There was some evidence that several body 280 composition and lung function measures were lower in cases than in controls between ages 45 to 65 281 (Supplement Figures 12 and 13). In male cases, the formal statistical test provided some evidence of 282 case-control differences in age-related changes in pulse rate, although it did not survive multiple testing 283 correction. None of the other formal statistical tests were statistically significant and there was less 284 evidence of case-control differences in age-related physiological changes (Supplement Figures 14 and 285 15).

286

### 287 Additional sensitivity analyses

Case-control differences in cardiovascular function by age were similar to the results of our main analysis after additional adjustment for BMI (Supplement Figures 16 and 17). Excluding anxiety disorder cases who reported current use of antidepressants (n = 6517 females and n = 2700 males)

had a negligible effect on case-control differences in blood pressure (Supplement Table 7).

# 292 **Discussion**

293

### 294 **Principal findings**

We observed case-control differences in hand-grip strength, blood pressure, pulse rate and body composition in both sexes, while case-control differences in lung function and heel bone mineral density were specific to females and males, respectively. We found no evidence of case-control differences in arterial stiffness.

299

300 Most of the observed differences were larger when we examined chronic and/or severe anxiety 301 disorders. However, in males, the difference in diastolic blood pressure was smaller and not statistically 302 significant, and differences in body fat percentage and heel bone mineral density, while similar in 303 magnitude, were no longer statistically significant.

304

After excluding cases with comorbid depression, most differences remained statistically significant but were smaller in magnitude. However, body composition measures in both sexes were either lower in cases, or we did not find evidence of case-control differences. We found some evidence that heel bone mineral density was lower in female cases without comorbid depression. Most case-control differences in lung function, however, were no longer statistically significant. We also did not find evidence of case-control differences in diastolic blood pressure in males without comorbid depression.

311

Differences in age-related physiological changes between female anxiety disorder cases and healthy controls were most evident for blood pressure, pulse rate and body composition, with some evidence of differences in heel bone mineral density. Most case-control differences narrowed with age, except that we found a larger difference in blood pressure in older participants. In males, case-control differences in hand-grip strength, pulse rate, and to a lesser extent in waist-hip ratio and heel bone mineral density narrowed with age. Diastolic blood pressure was lower in older cases than in controls.

318

The overall pattern of results was comparable in female chronic and/or severe cases, but there was generally less evidence of differences between trajectories in males. Except for body composition, there was limited evidence of case-control differences in age-related physiological changes after excluding individuals with comorbid depression.

323

### 324 Findings in context

325 Consistent with findings from the Netherland Study of Depression and Anxiety (NESDA)(12), female

326 cases had a lower hand-grip strength. Hand-grip strength was also lower in male cases, which had not

327 been observed in the NESDA.

#### 328

329 Previous findings regarding anxiety disorders and blood pressure have been mixed and studies have 330 often examined hypertension instead of blood pressure(30-33). While a recent meta-analysis reported 331 increased rates of hypertension in anxiety disorders(14), several studies found no statistically significant 332 associations with hypertension or blood pressure(34-38). Some studies observed lower blood pressure 333 in anxiety disorders(39-41). Antidepressant medication and benzodiazepine use may affect blood 334 pressure(42-44), and some population-based studies have observed lower blood pressure in 335 depression(16, 42). The high degree of comorbidity between anxiety disorders and depression and 336 differences in medication use might partially explain these mixed results. We observed lower blood 337 pressure in anxiety disorders, except for diastolic blood pressure in males, irrespective of depressive 338 comorbidity. Excluding individuals who reported antidepressant use at baseline resulted in a negligible 339 decrease in the case-control difference in systolic blood pressure and a negligible increase in the 340 difference in diastolic blood pressure. Case-control differences in blood pressure were larger in chronic 341 and/or severe anxiety disorders.

342

343 Consistent with previous research(45, 46), we observed a higher pulse rate in anxiety disorder cases. 344 Noteworthy, reductions in anxiety disorder severity following cognitive behavioural therapy have been 345 associated with a decrease in resting pulse rate(47).

346

347 Previous research has found higher rates of obesity(48, 49) and poor diet(50) in anxiety disorders, 348 consistent with our observation that cases had elevated measures of body composition. However, our 349 analyses suggested that these differences may be modified by depression comorbidity. Depression has 350 been associated with increased metabolic risk factors(51) and elevated body composition measures(16). 351 One study found that depression, but not anxiety disorders, was associated with an increased risk of 352 metabolic syndrome(52), although a large Finnish birth cohort study found no evidence that either 353 depression or anxiety disorders were associated with metabolic syndrome(53).

354

355 Our lung function results contradict previous research. A cross-sectional analysis of the NESDA found 356 poorer lung function in females with anxiety disorders and/or depression compared to healthy controls 357 and better lung function in male cases than in controls(54). A 6-year longitudinal assessment of these 358 participants suggested a greater decline in lung function in male cases compared to controls(12). We 359 observed better lung function in female cases and found no statistically significant case-control 360 differences in males. However, we observed no evidence of differences after excluding individuals with 361 comorbid depression. Noteworthy, the results from the NESDA were not reported separately for anxiety 362 disorders and depression.

363

medRxiv preprint doi: https://doi.org/10.1101/2021.08.15.21262059; this version posted November 7, 2021. The copyright holder for this 

364 Our results confirm previous research(55) that found a lower bone mineral density in male cases and 365 limited evidence of a case-control difference in females.

366

367 We did not observe any differences in arterial stiffness between cases and controls. This finding is 368 surprising given that previous studies have reported increased arterial stiffness in anxiety disorders(56, 369 57).

370

371 Inconsistencies in findings between studies could result from differences in sample characteristics such 372 as age, sex, severity of symptoms or the prevalence of effect modifiers. Systematic reviews of studies 373 examining each measure of physiological function in relation to anxiety disorders could address these 374 important questions. The definition of anxiety disorders, including which specific diagnoses were 375 included, might also contribute to differences in results.

376

377 To our knowledge, we report the first study of age-related changes in physiology in anxiety disorders 378 with age as a continuous rather than a categorical variable. Previous studies dichotomised age, for 379 example testing differences between middle-aged participants and others(14), making comparisons 380 with our study difficult.

381

#### 382 Mechanisms

383 Several mechanisms could explain the physiological differences between anxiety disorders cases and 384 healthy controls. Anxiety disorders are sometimes associated with less healthy lifestyle behaviours(58) 385 which could affect a range of physiological makers. Physiological differences could also reflect the 386 cumulative effects of anxiety-related overactivation of the hypothalamic-pituitary-adrenal axis and 387 sympathetic nervous system(33) as well as increased inflammation and oxidative stress(59-61). It is 388 also possible that the reciprocal relationship between late-life anxiety and associated cognitive 389 impairment may be a driver of poor physiological function(62). The greater case-control differences 390 observed in chronic and/or severe anxiety disorders could be explained by a dose-response relationship 391 between severity of symptoms and physiology mediated by a greater impact of anxiety on lifestyle, 392 overactivation of the sympathetic nervous system and other potential pathways. A potential explanation 393 for the observation that case-control differences decreased with increasing age is that the prevalence of 394 comorbidities increases with age which may dilute the effects that anxiety disorders may have.

395

#### 396 Limitations

397 The cross-sectional study design presents uncertainty about whether case-control differences by age 398 represent changes due to ageing or potential cohort effects. Future work should examine physiological 399

function in anxiety disorders longitudinally. Although we found that all physiological measures varied 400

401 group could result in the underestimation of age-related changes. To achieve maximum cohort 402 coverage, we identified cases from multiple data sources, with strengths and limitations that have been 403 discussed elsewhere(23, 63, 64). For the primary care records, we included the additional quality control 404 criterion that cases needed to have at least two mentions of anxiety in their records. Anxiety disorder 405 cases in this study also included individuals with a single episode. This likely resulted in an 406 underestimation of case-control differences. A small number of individuals with subthreshold disorders 407 could be present amongst the healthy controls, which could have attenuated observed differences. We 408 examined a transdiagnostic definition of anxiety disorders, and differences in physiological function 409 between specific diagnoses could be explored in future studies. Although we found that the differences 410 between individuals with chronic and/or severe anxiety disorders and controls were larger, these 411 differences could at least partly reflect higher levels of comorbidities in addition to the effects of 412 chronicity and/or severity. Some caution is warranted in interpreting the findings of the sensitivity 413 analyses due to the smaller sample size and lower statistical power. Finally, limitations in the 414 assessment of physiological function may have masked some differences between cases and controls. 415 For example, dynamic measures such as pulse rate were not measured longitudinally, and our study 416 does therefore not provide insights into potential case-control differences that could be identified from 417 time-series data. Similarly, lung function was estimated through volumetric measures using breath 418 spirometry and we could therefore not examine irregularity of respiratory patterns. Physiological 419 measures with higher temporal resolution could be examined in future studies.

420

#### 421 Generalisability

422 UK Biobank participants are not fully representative of the UK population. MHQ respondents were 423 also more educated, of higher socioeconomic status and had fewer long-standing illnesses than 424 participants who did not complete the MHQ. Similar patterns of disease prevalence were present in the 425 MHQ and hospital inpatient records, although anxiety was reported more frequently in the MHQ(18). 426 Nevertheless, the overall number of individuals with a lifetime history of anxiety disorders identified 427 in our study was comparable to previous epidemiological studies (65). Wider issues of generalisability 428 of findings from the UK Biobank have been discussed elsewhere(66). Our findings do not generalise to 429 populations below age 40 or older than age 70, and there was greater uncertainty near the lower and 430 upper extremes of the age range in this study. Additional studies in younger participants and in the 431 elderly are needed.

432

#### 433 Implications

434 Individuals with a lifetime history of anxiety disorders differed from healthy controls across multiple 435 physiological measures, with some evidence of case-control differences by age. The differences 436 observed varied by chronicity/severity and depression comorbidity. Monitoring of physiological

- 437 function in individuals with anxiety disorders should be adapted depending on depression comorbidity
- 438 status.

#### 439 Ethics

- 440 We assert that all procedures contributing to this work comply with the ethical standards of the relevant
- 441 national and institutional committees on human experimentation. All procedures were approved for the
- 442 UK Biobank study by the National Information Governance Board for Health and Social Care and the
- 443 NHS North West Multicentre Research Ethics Committee (11/NW/0382). No project-specific ethical
- 444 approval is needed. Data access permission has been granted under UK Biobank application 45514.
- 445 Written informed consent was obtained from all participants.
- 446

#### 447 **Declaration of Interest**

- 448 JM receives studentship funding from the Biotechnology and Biological Sciences Research Council
- 449 (BBSRC) and Eli Lilly and Company Limited. CML is a member of the Scientific Advisory Board of
- 450 Myriad Neuroscience. CF has been a speaker for Janssen. THH declares no relevant conflict of interest.
- 451

#### 452 Funding

453 JM receives studentship funding from the Biotechnology and Biological Sciences Research Council 454 (BBSRC) (ref: 2050702) and Eli Lilly and Company Limited. CF was supported by Fondazione 455 Umberto Veronesi (https://www.fondazioneveronesi.it). CML is part-funded by the National Institute 456 for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley 457 NHS Foundation Trust and King's College London. The views expressed are those of the authors and 458 not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

459

#### 460 Acknowledgments

461 This research has been conducted using data from UK Biobank, a major biomedical database. This project made use of time on Rosalind HPC, funded by Guy's & St Thomas' Hospital NHS Trust 462 463 Biomedical Research Centre (GSTT-BRC), South London & Maudsley NHS Trust Biomedical 464 Research Centre (SLAM-BRC), and Faculty of Natural Mathematics & Science (NMS) at King's 465 College London.

466

#### 467 **Author Contribution**

468 CML acquired the studentship funding, interpreted the findings and critically reviewed the manuscript. 469 JM conceived the idea of the study, acquired the data, carried out the statistical analysis, interpreted the 470 findings, wrote the manuscript and revised the manuscript for final submission. THH contributed to the 471 study design, interpreted the findings and contributed to the writing of the manuscript. CF interpreted 472 the findings and critically reviewed the manuscript. All authors read and approved the final manuscript. 473 JM had full access to all data used in this study and takes responsibility for the integrity of the data and 474 the accuracy of the data analysis.

475

#### 476 **Data Availability**

- 477 The data used are available to all bona fide researchers for health-related research that is in the public
- 478 interest, subject to an application process and approval criteria. Study materials are publicly available
- 479 online at http://www.ukbiobank.ac.uk.

perpetuity. It is made available under a CC-BY 4.0 International license .

# 480 **References**

### 481

482 Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 1. 483 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global 484 Burden of Disease Study 2019. The Lancet. 2020;396(10258):1204-22. 485 Baxter AJ, Scott K, Vos T, Whiteford H. Global prevalence of anxiety disorders: a systematic 2. 486 review and meta-regression. Psychological Medicine. 2013;43(5):897-910. 487 3. Hovenkamp-Hermelink JH, Jeronimus BF, Myroniuk S, Riese H, Schoevers RA. Predictors 488 of persistence of anxiety disorders across the lifespan: a systematic review. The Lancet Psychiatry. 489 2021;8(5):428-43. 490 4. Markkula N, Härkänen T, Perälä J, Partti K, Pena S, Koskinen S, et al. Mortality in people 491 with depressive, anxiety and alcohol use disorders in Finland. The British Journal of Psychiatry. 492 2012;200(2):143-9. 493 Meier SM, Mattheisen M, Mors O, Mortensen PB, Laursen TM, Penninx BW. Increased 5. 494 mortality among people with anxiety disorders: total population study. The British Journal of 495 Psychiatry. 2016;209(3):216-21. 496 Perna G, Iannone G, Alciati A, Caldirola D. Are anxiety disorders associated with accelerated 6. 497 aging? A focus on neuroprogression. Neural Plasticity. 2016;2016. 498 Karim HT, Ly M, Yu G, Krafty R, Tudorascu DL, Aizenstein HJ, et al. Aging faster: worry 7. 499 and rumination in late life are associated with greater brain age. Neurobiology of Aging. 2021;101:13-500 21. 501 8. Malouff JM, Schutte NS. A meta-analysis of the relationship between anxiety and telomere 502 length. Anxiety, Stress, & Coping. 2017;30(3):264-72. 503 9. Verhoeven JE, Révész D, van Oppen P, Epel ES, Wolkowitz OM, Penninx BW. Anxiety 504 disorders and accelerated cellular ageing. The British Journal of Psychiatry. 2015;206(5):371-8. 505 Brenes GA, Guralnik JM, Williamson JD, Fried LP, Simpson C, Simonsick EM, et al. The 10. 506 influence of anxiety on the progression of disability. Journal of the American Geriatrics Society. 507 2005;53(1):34-9. 508 Brenes GA, Penninx BW, Judd PH, Rockwell E, Sewell DD, Wetherell JL. Anxiety, 11. 509 depression and disability across the lifespan. Aging and Mental Health. 2008;12(1):158-63. 510 12. Lever-van Milligen BA, Lamers F, Smit JH, Penninx BW. Six-year trajectory of objective 511 physical function in persons with depressive and anxiety disorders. Depression and Anxiety. 512 2017;34(2):188-97. 513 Goodwin RD, Chuang S, Simuro N, Davies M, Pine DS. Association between lung function 13. 514 and mental health problems among adults in the United States: findings from the First National Health 515 and Nutrition Examination Survey. American Journal of Epidemiology. 2007;165(4):383-8. 516 Pan Y, Cai W, Cheng Q, Dong W, An T, Yan J. Association between anxiety and 14. 517 hypertension: a systematic review and meta-analysis of epidemiological studies. Neuropsychiatric 518 Disease and Treatment. 2015;11:1121-30. 519 15. Austad SN, Bartke A. Sex differences in longevity and in responses to anti-aging 520 interventions: a mini-review. Gerontology. 2016;62(1):40-6. 521 Mutz J, Lewis CM. Lifetime depression and age-related changes in body composition, 16. 522 cardiovascular function, grip strength and lung function: sex-specific analyses in the UK Biobank. 523 Aging. 2021;13(13):17038-79. 524 Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank 17. 525 resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203-9. Davis KA, Coleman JR, Adams M, Allen N, Breen G, Cullen B, et al. Mental health in UK 526 18. 527 Biobank-development, implementation and results from an online questionnaire completed by 157 528 366 participants: a reanalysis. BJPsych Open. 2020;6(2):E18. 529 Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-19. 7 and GAD-2: a systematic review and diagnostic metaanalysis. General Hospital Psychiatry. 530 531 2016;39:24-31.

Fabbri C, Hagenaars SP, John C, Williams AT, Shrine N, Moles L, et al. Genetic and clinical 532 20. 533 characteristics of treatment-resistant depression using primary care records in two UK cohorts. 534 Molecular Psychiatry. 2021. 535 Stubbs B, Koyanagi A, Veronese N, Vancampfort D, Solmi M, Gaughran F, et al. Physical 21. 536 multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people 537 across 48 low-and middle-income countries. BMC Medicine. 2016;14(1):1-12. 538 Smith DJ, Martin D, McLean G, Langan J, Guthrie B, Mercer SW. Multimorbidity in bipolar 22. 539 disorder and undertreatment of cardiovascular disease: a cross sectional study. BMC Medicine. 540 2013;11(1):1-11. 541 Davis KA, Cullen B, Adams M, Brailean A, Breen G, Coleman JR, et al. Indicators of mental 23. 542 disorders in UK Biobank-A comparison of approaches. International Journal of Methods in 543 Psychiatric Research. 2019;28(3):e1796. 544 24. Smith DJ, Nicholl BI, Cullen B, Martin D, Ul-Haq Z, Evans J, et al. Prevalence and 545 characteristics of probable major depression and bipolar disorder within UK biobank: cross-sectional 546 study of 172,751 participants. PloS One. 2013;8(11):e75362. 547 Mutz J, Young AH, Lewis CM. Age-related changes in physiology in individuals with bipolar 25. 548 disorder. Journal of Affective Disorders. 2021. 549 Guggenheim JA, Williams C. Childhood febrile illness and the risk of myopia in UK Biobank 26. 550 participants. Eye. 2016;30(4):608-14. 551 27. Mutz J, Roscoe CJ, Lewis CM. Exploring health in the UK Biobank: associations with 552 sociodemographic characteristics, psychosocial factors, lifestyle and environmental exposures. BMC 553 Medicine. 2021;19(1):240. 554 Wood SN. Generalized additive models: an introduction with R: CRC press; 2017. 28. 555 29. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful 556 approach to multiple testing. Journal of the Royal Statistical Society: Series B (Methodological). 557 1995;57(1):289-300. 558 30. Byrd JB, Brook RD. Anxiety in the "age of hypertension". Current Hypertension Reports. 559 2014;16(10):1-7. 560 31. Cuffee Y, Ogedegbe C, Williams NJ, Ogedegbe G, Schoenthaler A. Psychosocial risk factors 561 for hypertension: an update of the literature. Current Hypertension Reports. 2014;16(10):483. 562 Player MS, Peterson LE. Anxiety disorders, hypertension, and cardiovascular risk: a review. 32. 563 The International Journal of Psychiatry in Medicine. 2011;41(4):365-77. 564 Cohen BE, Edmondson D, Kronish IM. State of the art review: depression, stress, anxiety, 33. 565 and cardiovascular disease. American Journal of Hypertension. 2015;28(11):1295-302. 566 Jackson CA, Pathirana T, Gardiner PA. Depression, anxiety and risk of hypertension in mid-34. 567 aged women: a prospective longitudinal study. Journal of Hypertension. 2016;34(10):1959-66. 568 35. Jones-Webb R, Jacobs Jr DR, Flack JM, Liu K. Relationships between depressive symptoms, 569 anxiety, alcohol consumption, and blood pressure: results from the CARDIA study. Alcoholism: 570 Clinical and Experimental Research. 1996;20(3):420-7. 571 36. Maatouk I, Herzog W, Böhlen F, Quinzler R, Löwe B, Saum K-U, et al. Association of 572 hypertension with depression and generalized anxiety symptoms in a large population-based sample 573 of older adults. Journal of Hypertension. 2016;34(9):1711-20. 574 37. Shinn EH, Poston WSC, Kimball KT, St. Jeor ST, Foreyt JP. Blood pressure and symptoms 575 of depression and anxiety: a prospective study. American Journal of Hypertension. 2001;14(7):660-4. 576 38. Yan LL, Liu K, Matthews KA, Daviglus ML, Ferguson TF, Kiefe CI. Psychosocial factors 577 and risk of hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) study. 578 JAMA. 2003;290(16):2138-48. 579 Huang Y, Su Y, Jiang Y, Zhu M. Sex differences in the associations between blood pressure 39. 580 and anxiety and depression scores in a middle-aged and elderly population: the Irish Longitudinal 581 Study on Ageing (TILDA). Journal of Affective Disorders. 2020;274:118-25. 582 40. Hildrum B, Romild U, Holmen J. Anxiety and depression lowers blood pressure: 22-year 583 follow-up of the population based HUNT study, Norway. BMC Public health. 2011;11(1):1-8. 584 41. Bhat SK, Beilin LJ, Robinson M, Burrows S, Mori TA. Relationships between depression and 585 anxiety symptoms scores and blood pressure in young adults. Journal of Hypertension. 586 2017;35(10):1983-91.

perpetuity. It is made available under a CC-BY 4.0 International license .

587 42. Licht CM, De Geus EJ, Seldenrijk A, Van Hout HP, Zitman FG, Van Dyck R, et al. 588 Depression is associated with decreased blood pressure, but antidepressant use increases the risk for 589 hypertension. Hypertension. 2009;53(4):631-8. 590 Zhong Z, Wang L, Wen X, Liu Y, Fan Y, Liu Z. A meta-analysis of effects of selective 43. 591 serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and 592 serotonin and noradrenaline reuptake inhibitor controlled trials. Neuropsychiatric Disease and 593 Treatment. 2017;13:2781-96. 594 Mendelson N, Gontmacher B, Vodonos A, Novack V, Abu-AjAj M, Wolak A, et al. 44. 595 Benzodiazepine consumption is associated with lower blood pressure in ambulatory blood pressure 596 monitoring (ABPM): retrospective analysis of 4938 ABPMs. American Journal of Hypertension. 597 2018;31(4):431-7. 598 Latvala A, Kuja-Halkola R, Rück C, D'Onofrio BM, Jernberg T, Almqvist C, et al. 45. 599 Association of resting heart rate and blood pressure in late adolescence with subsequent mental 600 disorders: a longitudinal population study of more than 1 million men in Sweden. JAMA Psychiatry. 601 2016;73(12):1268-75. 602 Thaver JF, Friedman BH, Borkovec TD. Autonomic characteristics of generalized anxiety 46. 603 disorder and worry. Biological Psychiatry. 1996;39(4):255-66. 604 Goncalves R, Rodrigues H, Novaes F, Arbol J, Volchan E, Coutinho ESF, et al. Listening to 47. 605 the heart: a meta-analysis of cognitive behavior therapy impact on the heart rate of patients with 606 anxiety disorders. Journal of Affective Disorders. 2015;172:231-40. 607 48. Gariepy G, Nitka D, Schmitz N. The association between obesity and anxiety disorders in the 608 population: a systematic review and meta-analysis. International Journal of Obesity. 2010;34(3):407-609 19. 610 49. Barry D, Pietrzak RH, Petry NM. Gender differences in associations between body mass 611 index and DSM-IV mood and anxiety disorders: results from the National Epidemiologic Survey on 612 Alcohol and Related Conditions. Annals of Epidemiology. 2008;18(6):458-66. 613 50. Gibson-Smith D, Bot M, Brouwer IA, Visser M, Penninx BW. Diet quality in persons with 614 and without depressive and anxiety disorders. Journal of Psychiatric Research. 2018;106:1-7. 615 McCaffery JM, Niaura R, Todaro JF, Swan GE, Carmelli D. Depressive symptoms and 51. 616 metabolic risk in adult male twins enrolled in the National Heart, Lung, and Blood Institute twin 617 study. Psychosomatic Medicine. 2003;65(3):490-7. 618 Skilton MR, Moulin P, Terra J-L, Bonnet F. Associations between anxiety, depression, and 52. 619 the metabolic syndrome. Biological Psychiatry. 2007;62(11):1251-7. 620 53. Herva A, Räsänen P, Miettunen J, Timonen M, Läksy K, Veijola J, et al. Co-occurrence of 621 metabolic syndrome with depression and anxiety in young adults: the Northern Finland 1966 Birth 622 Cohort Study. Psychosomatic Medicine. 2006;68(2):213-6. 623 van Milligen BA, Lamers F, Guus T, Smit JH, Penninx BW. Objective physical functioning 54. 624 in patients with depressive and/or anxiety disorders. Journal of Affective Disorders. 2011;131(1-625 3):193-9. 626 55. Williams LJ, Pasco JA, Jacka FN, Hodge JM, Kotowicz MA, Berk M. Quantitative Heel 627 Ultrasound (QUS) measures of bone quality in association with mood and anxiety disorders. Journal 628 of Affective Disorders. 2013;146(3):395-400. 629 Seldenrijk A, van Hout HP, van Marwijk HW, de Groot E, Gort J, Rustemeijer C, et al. 56. 630 Depression, anxiety, and arterial stiffness. Biological Psychiatry. 2011;69(8):795-803. Yeragani VK, Kumar R, Bar KJ, Chokka P, Tancer M. Exaggerated differences in pulse wave 631 57. 632 velocity between left and right sides among patients with anxiety disorders and cardiovascular 633 disease. Psychosomatic Medicine. 2007;69(8):717-22. 634 Bonnet F, Irving K, Terra J-L, Nony P, Berthezène F, Moulin P. Anxiety and depression are 58. 635 associated with unhealthy lifestyle in patients at risk of cardiovascular disease. Atherosclerosis. 636 2005;178(2):339-44. 637 59. Vogelzangs N, Beekman A, De Jonge P, Penninx B. Anxiety disorders and inflammation in a 638 large adult cohort. Translational Psychiatry. 2013;3(4):e249-e. 639 60. Michopoulos V, Powers A, Gillespie CF, Ressler KJ, Jovanovic T. Inflammation in fear-and

640 anxiety-based disorders: PTSD, GAD, and beyond. Neuropsychopharmacology. 2017;42(1):254-70.

perpetuity. It is made available under a CC-BY 4.0 International license .

- 641 61. Black C, Bot M, Scheffer P, Penninx B. Oxidative stress in major depressive and anxiety
- disorders, and the association with antidepressant use; results from a large adult cohort. PsychologicalMedicine. 2017;47(5):936-48.
- 644 62. Beaudreau SA, O'Hara R. Late-life anxiety and cognitive impairment: a review. The 645 American Journal of Geriatric Psychiatry. 2008;16(10):790-803.
- 646 63. Davis K, Hotopf M. Mental health phenotyping in UK Biobank. Progress in Neurology and 647 Psychiatry. 2019;23(1):4-7.
- 648 64. Glanville KP, Coleman JR, Howard DM, Pain O, Hanscombe KB, Jermy B, et al. Multiple
- 649 measures of depression to enhance validity of Major Depressive Disorder in the UK Biobank.
- 650 BJPsych Open. 2021;7(2):e44.
- 651 65. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues 652 Clin Neurosci. 2015;17(3):327-35.
- 653 66. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of
- 654 sociodemographic and health-related characteristics of UK Biobank participants with those of the
- general population. American Journal of Epidemiology. 2017;186(9):1026-34.

656